Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,9352572,plasma concentrations,"Thioridazine also significantly increased plasma concentrations of both S-desmethylmianserin (11.9 +/- 2.8 vs. 24.4 +/- 10.7 nM, P < 0.01) and R-desmethylmianserin (42.6 +/- 28.4 vs. 115.6 +/- 36.9 nM, P < 0.001).","Effects of thioridazine, an inhibitor of CYP2D6, on the steady-state plasma concentrations of the enantiomers of mianserin and its active metabolite, desmethylmianserin, in depressed Japanese patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9352572/),nM,11.9,961,DB06148,Mianserin
,9352572,plasma concentrations,"Thioridazine also significantly increased plasma concentrations of both S-desmethylmianserin (11.9 +/- 2.8 vs. 24.4 +/- 10.7 nM, P < 0.01) and R-desmethylmianserin (42.6 +/- 28.4 vs. 115.6 +/- 36.9 nM, P < 0.001).","Effects of thioridazine, an inhibitor of CYP2D6, on the steady-state plasma concentrations of the enantiomers of mianserin and its active metabolite, desmethylmianserin, in depressed Japanese patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9352572/),nM,24.4,962,DB06148,Mianserin
,9352572,plasma concentrations,"Thioridazine also significantly increased plasma concentrations of both S-desmethylmianserin (11.9 +/- 2.8 vs. 24.4 +/- 10.7 nM, P < 0.01) and R-desmethylmianserin (42.6 +/- 28.4 vs. 115.6 +/- 36.9 nM, P < 0.001).","Effects of thioridazine, an inhibitor of CYP2D6, on the steady-state plasma concentrations of the enantiomers of mianserin and its active metabolite, desmethylmianserin, in depressed Japanese patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9352572/),nM,42.6,963,DB06148,Mianserin
,9352572,plasma concentrations,"Thioridazine also significantly increased plasma concentrations of both S-desmethylmianserin (11.9 +/- 2.8 vs. 24.4 +/- 10.7 nM, P < 0.01) and R-desmethylmianserin (42.6 +/- 28.4 vs. 115.6 +/- 36.9 nM, P < 0.001).","Effects of thioridazine, an inhibitor of CYP2D6, on the steady-state plasma concentrations of the enantiomers of mianserin and its active metabolite, desmethylmianserin, in depressed Japanese patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9352572/),nM,115.6,964,DB06148,Mianserin
,7550984,detection limit,The assay allowed the simultaneous determination of all analytes in 1 ml of urine and the detection limit was 2 ng/ml with a signal-to-noise ratio of 3.,Development and preliminary application of high-performance liquid chromatographic assay of urinary metabolites of diazepam in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7550984/),[ng] / [ml],2,6147,DB06148,Mianserin
,7550984,signal-to-noise ratio,The assay allowed the simultaneous determination of all analytes in 1 ml of urine and the detection limit was 2 ng/ml with a signal-to-noise ratio of 3.,Development and preliminary application of high-performance liquid chromatographic assay of urinary metabolites of diazepam in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7550984/),,3,6148,DB06148,Mianserin
>,7550984,Recoveries,Recoveries of the analytes and the internal standard (prazepam) were > 82%.,Development and preliminary application of high-performance liquid chromatographic assay of urinary metabolites of diazepam in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7550984/),%,82,6149,DB06148,Mianserin
,7550984,cumulative urinary excretions,"The mean (+/- S.D.) cumulative urinary excretions of DMDZP, TZP and OZP over 96 h after a single oral administration of DZP were 3.9 +/- 0.4, 6.6 +/- 1.4 and 2.8 +/- 0.6% of the dose, respectively.",Development and preliminary application of high-performance liquid chromatographic assay of urinary metabolites of diazepam in humans. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7550984/),%,3.9,6150,DB06148,Mianserin
,7550984,cumulative urinary excretions,"The mean (+/- S.D.) cumulative urinary excretions of DMDZP, TZP and OZP over 96 h after a single oral administration of DZP were 3.9 +/- 0.4, 6.6 +/- 1.4 and 2.8 +/- 0.6% of the dose, respectively.",Development and preliminary application of high-performance liquid chromatographic assay of urinary metabolites of diazepam in humans. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7550984/),%,6.6,6151,DB06148,Mianserin
,7550984,cumulative urinary excretions,"The mean (+/- S.D.) cumulative urinary excretions of DMDZP, TZP and OZP over 96 h after a single oral administration of DZP were 3.9 +/- 0.4, 6.6 +/- 1.4 and 2.8 +/- 0.6% of the dose, respectively.",Development and preliminary application of high-performance liquid chromatographic assay of urinary metabolites of diazepam in humans. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7550984/),%,2.8,6152,DB06148,Mianserin
,12242602,AUC(0-24),The addition of phenytoin to an existing daily administration of mirtazapine resulted in a mean (+/-SD) decrease of the AUC(0-24) from 576+/-104 ng h/ml to 305+/-81.6 ng h/ml and a mean decrease of C(max) from 69.7+/-17.5 ng/ml to 46.9+/-10.9 ng/ml.,Concomitant use of mirtazapine and phenytoin: a drug-drug interaction study in healthy male subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12242602/),[h·ng] / [ml],576,11429,DB06148,Mianserin
,12242602,AUC(0-24),The addition of phenytoin to an existing daily administration of mirtazapine resulted in a mean (+/-SD) decrease of the AUC(0-24) from 576+/-104 ng h/ml to 305+/-81.6 ng h/ml and a mean decrease of C(max) from 69.7+/-17.5 ng/ml to 46.9+/-10.9 ng/ml.,Concomitant use of mirtazapine and phenytoin: a drug-drug interaction study in healthy male subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12242602/),[h·ng] / [ml],305,11430,DB06148,Mianserin
,12242602,C(max),The addition of phenytoin to an existing daily administration of mirtazapine resulted in a mean (+/-SD) decrease of the AUC(0-24) from 576+/-104 ng h/ml to 305+/-81.6 ng h/ml and a mean decrease of C(max) from 69.7+/-17.5 ng/ml to 46.9+/-10.9 ng/ml.,Concomitant use of mirtazapine and phenytoin: a drug-drug interaction study in healthy male subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12242602/),[ng] / [ml],69.7,11431,DB06148,Mianserin
,12242602,C(max),The addition of phenytoin to an existing daily administration of mirtazapine resulted in a mean (+/-SD) decrease of the AUC(0-24) from 576+/-104 ng h/ml to 305+/-81.6 ng h/ml and a mean decrease of C(max) from 69.7+/-17.5 ng/ml to 46.9+/-10.9 ng/ml.,Concomitant use of mirtazapine and phenytoin: a drug-drug interaction study in healthy male subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12242602/),[ng] / [ml],46.9,11432,DB06148,Mianserin
,22139691,encapsulation efficiency,The encapsulation efficiency of different formulation varied from 53 ± 1.2% to 78 ± 1.5%.,Controlled release chitosan microspheres of mirtazapine: in vitro and in vivo evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22139691/),%,53,26542,DB06148,Mianserin
,22139691,encapsulation efficiency,The encapsulation efficiency of different formulation varied from 53 ± 1.2% to 78 ± 1.5%.,Controlled release chitosan microspheres of mirtazapine: in vitro and in vivo evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22139691/),%,78,26543,DB06148,Mianserin
,22139691,particle size,The mean particle size of the optimized formulation F-14 was 106.4 ± 0.5 μm.,Controlled release chitosan microspheres of mirtazapine: in vitro and in vivo evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22139691/),μm,106.4,26544,DB06148,Mianserin
,22139691,AUC,"Pharmacokinetic studies revealed that the optimized formulation showed significant increases in systemic exposure (AUC = 177.70 ± 7.39 μg·h/mL), half-life (4.72 ± 0.46 h) and reduced clearance (0.009 ± 0.0001 L/h) compared to pure drug administration.",Controlled release chitosan microspheres of mirtazapine: in vitro and in vivo evaluation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22139691/),[h·μg] / [ml],177.70,26545,DB06148,Mianserin
,22139691,half-life,"Pharmacokinetic studies revealed that the optimized formulation showed significant increases in systemic exposure (AUC = 177.70 ± 7.39 μg·h/mL), half-life (4.72 ± 0.46 h) and reduced clearance (0.009 ± 0.0001 L/h) compared to pure drug administration.",Controlled release chitosan microspheres of mirtazapine: in vitro and in vivo evaluation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22139691/),h,4.72,26546,DB06148,Mianserin
,22139691,clearance,"Pharmacokinetic studies revealed that the optimized formulation showed significant increases in systemic exposure (AUC = 177.70 ± 7.39 μg·h/mL), half-life (4.72 ± 0.46 h) and reduced clearance (0.009 ± 0.0001 L/h) compared to pure drug administration.",Controlled release chitosan microspheres of mirtazapine: in vitro and in vivo evaluation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22139691/),[l] / [h],0.009,26547,DB06148,Mianserin
,6576394,absorption half-life,"Mean (+/- SD) estimates were: absorption half-life 0.8 +/- 1.0h, peak concentration 117 +/- 23 micrograms/l, peak time 2.2 +/- 1.3h, distribution half-life 3.4 +/- 1.2h, elimination half-life 33 +/- 15h, apparent volume of distribution 20.2 +/- 7.9 1/kg, and oral clearance 0.49 +/- 0.21 l/kg/h.",The pharmacokinetics of mianserin in elderly depressed patients. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6576394/),h,0.8,54294,DB06148,Mianserin
,6576394,peak concentration,"Mean (+/- SD) estimates were: absorption half-life 0.8 +/- 1.0h, peak concentration 117 +/- 23 micrograms/l, peak time 2.2 +/- 1.3h, distribution half-life 3.4 +/- 1.2h, elimination half-life 33 +/- 15h, apparent volume of distribution 20.2 +/- 7.9 1/kg, and oral clearance 0.49 +/- 0.21 l/kg/h.",The pharmacokinetics of mianserin in elderly depressed patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6576394/),[μg] / [l],117,54295,DB06148,Mianserin
,6576394,peak time,"Mean (+/- SD) estimates were: absorption half-life 0.8 +/- 1.0h, peak concentration 117 +/- 23 micrograms/l, peak time 2.2 +/- 1.3h, distribution half-life 3.4 +/- 1.2h, elimination half-life 33 +/- 15h, apparent volume of distribution 20.2 +/- 7.9 1/kg, and oral clearance 0.49 +/- 0.21 l/kg/h.",The pharmacokinetics of mianserin in elderly depressed patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6576394/),h,2.2,54296,DB06148,Mianserin
,6576394,distribution half-life,"Mean (+/- SD) estimates were: absorption half-life 0.8 +/- 1.0h, peak concentration 117 +/- 23 micrograms/l, peak time 2.2 +/- 1.3h, distribution half-life 3.4 +/- 1.2h, elimination half-life 33 +/- 15h, apparent volume of distribution 20.2 +/- 7.9 1/kg, and oral clearance 0.49 +/- 0.21 l/kg/h.",The pharmacokinetics of mianserin in elderly depressed patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6576394/),h,3.4,54297,DB06148,Mianserin
,6576394,elimination half-life,"Mean (+/- SD) estimates were: absorption half-life 0.8 +/- 1.0h, peak concentration 117 +/- 23 micrograms/l, peak time 2.2 +/- 1.3h, distribution half-life 3.4 +/- 1.2h, elimination half-life 33 +/- 15h, apparent volume of distribution 20.2 +/- 7.9 1/kg, and oral clearance 0.49 +/- 0.21 l/kg/h.",The pharmacokinetics of mianserin in elderly depressed patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6576394/),h,33,54298,DB06148,Mianserin
,6576394,apparent volume of distribution,"Mean (+/- SD) estimates were: absorption half-life 0.8 +/- 1.0h, peak concentration 117 +/- 23 micrograms/l, peak time 2.2 +/- 1.3h, distribution half-life 3.4 +/- 1.2h, elimination half-life 33 +/- 15h, apparent volume of distribution 20.2 +/- 7.9 1/kg, and oral clearance 0.49 +/- 0.21 l/kg/h.",The pharmacokinetics of mianserin in elderly depressed patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6576394/),[1] / [kg],20.2,54299,DB06148,Mianserin
,6576394,oral clearance,"Mean (+/- SD) estimates were: absorption half-life 0.8 +/- 1.0h, peak concentration 117 +/- 23 micrograms/l, peak time 2.2 +/- 1.3h, distribution half-life 3.4 +/- 1.2h, elimination half-life 33 +/- 15h, apparent volume of distribution 20.2 +/- 7.9 1/kg, and oral clearance 0.49 +/- 0.21 l/kg/h.",The pharmacokinetics of mianserin in elderly depressed patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6576394/),[l] / [h·kg],0.49,54300,DB06148,Mianserin
,6576394,absorption lag time,The absorption lag time (0.6 +/- 0.2h) and area under the curve (2009 +/- 566 micrograms/l/h) were significantly different in the elderly.,The pharmacokinetics of mianserin in elderly depressed patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6576394/),h,0.6,54301,DB06148,Mianserin
,6576394,area under the curve,The absorption lag time (0.6 +/- 0.2h) and area under the curve (2009 +/- 566 micrograms/l/h) were significantly different in the elderly.,The pharmacokinetics of mianserin in elderly depressed patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6576394/),[μg] / [h·l],2009,54302,DB06148,Mianserin
,1491054,recovery,Calibration curves were linear to at least 53.7 ng/ml at which the between-day relative standard deviation was 5% and the recovery 101%.,Automated high-performance liquid chromatographic method for the determination of mianserin in plasma using electrochemical detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1491054/),%,101,56609,DB06148,Mianserin
,1491054,recovery,The limit of quantification was 1.67 ng/ml at which the between-day relative standard deviation was 9% and the recovery 92% using a sample volume of 0.5 ml.,Automated high-performance liquid chromatographic method for the determination of mianserin in plasma using electrochemical detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1491054/),%,92,56610,DB06148,Mianserin
,22541842,C(max),"The main PK parameters of the mirtazapine test and reference tables were as follows: mean (SD) C(max), 58.715 (23.89) and 58.255 (22.34) ng/ml; AUC(0-t), 591.406 (186.79) and 596.339 (201.25) ng × h/ml; AUC(0-∞), 627.03 (201.39) and 631.521 (227.32) ng × h/ml; t(1/2), 18.941 (4.79) and 18.285 (3.91) h; t(max) 1.417 (0.61) and 1.424 (0.75) h.",Bioequivalence study of two mirtazapine oral tablet formulations in healthy Chinese male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22541842/),[ng] / [ml],58.715,61941,DB06148,Mianserin
,22541842,C(max),"The main PK parameters of the mirtazapine test and reference tables were as follows: mean (SD) C(max), 58.715 (23.89) and 58.255 (22.34) ng/ml; AUC(0-t), 591.406 (186.79) and 596.339 (201.25) ng × h/ml; AUC(0-∞), 627.03 (201.39) and 631.521 (227.32) ng × h/ml; t(1/2), 18.941 (4.79) and 18.285 (3.91) h; t(max) 1.417 (0.61) and 1.424 (0.75) h.",Bioequivalence study of two mirtazapine oral tablet formulations in healthy Chinese male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22541842/),[ng] / [ml],58.255,61942,DB06148,Mianserin
,22541842,AUC(0-t),"The main PK parameters of the mirtazapine test and reference tables were as follows: mean (SD) C(max), 58.715 (23.89) and 58.255 (22.34) ng/ml; AUC(0-t), 591.406 (186.79) and 596.339 (201.25) ng × h/ml; AUC(0-∞), 627.03 (201.39) and 631.521 (227.32) ng × h/ml; t(1/2), 18.941 (4.79) and 18.285 (3.91) h; t(max) 1.417 (0.61) and 1.424 (0.75) h.",Bioequivalence study of two mirtazapine oral tablet formulations in healthy Chinese male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22541842/),[h·ng] / [ml],591.406,61943,DB06148,Mianserin
,22541842,AUC(0-t),"The main PK parameters of the mirtazapine test and reference tables were as follows: mean (SD) C(max), 58.715 (23.89) and 58.255 (22.34) ng/ml; AUC(0-t), 591.406 (186.79) and 596.339 (201.25) ng × h/ml; AUC(0-∞), 627.03 (201.39) and 631.521 (227.32) ng × h/ml; t(1/2), 18.941 (4.79) and 18.285 (3.91) h; t(max) 1.417 (0.61) and 1.424 (0.75) h.",Bioequivalence study of two mirtazapine oral tablet formulations in healthy Chinese male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22541842/),[h·ng] / [ml],596.339,61944,DB06148,Mianserin
,22541842,AUC(0-∞),"The main PK parameters of the mirtazapine test and reference tables were as follows: mean (SD) C(max), 58.715 (23.89) and 58.255 (22.34) ng/ml; AUC(0-t), 591.406 (186.79) and 596.339 (201.25) ng × h/ml; AUC(0-∞), 627.03 (201.39) and 631.521 (227.32) ng × h/ml; t(1/2), 18.941 (4.79) and 18.285 (3.91) h; t(max) 1.417 (0.61) and 1.424 (0.75) h.",Bioequivalence study of two mirtazapine oral tablet formulations in healthy Chinese male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22541842/),[h·ng] / [ml],627.03,61945,DB06148,Mianserin
,22541842,AUC(0-∞),"The main PK parameters of the mirtazapine test and reference tables were as follows: mean (SD) C(max), 58.715 (23.89) and 58.255 (22.34) ng/ml; AUC(0-t), 591.406 (186.79) and 596.339 (201.25) ng × h/ml; AUC(0-∞), 627.03 (201.39) and 631.521 (227.32) ng × h/ml; t(1/2), 18.941 (4.79) and 18.285 (3.91) h; t(max) 1.417 (0.61) and 1.424 (0.75) h.",Bioequivalence study of two mirtazapine oral tablet formulations in healthy Chinese male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22541842/),[h·ng] / [ml],631.521,61946,DB06148,Mianserin
,22541842,t(1/2),"The main PK parameters of the mirtazapine test and reference tables were as follows: mean (SD) C(max), 58.715 (23.89) and 58.255 (22.34) ng/ml; AUC(0-t), 591.406 (186.79) and 596.339 (201.25) ng × h/ml; AUC(0-∞), 627.03 (201.39) and 631.521 (227.32) ng × h/ml; t(1/2), 18.941 (4.79) and 18.285 (3.91) h; t(max) 1.417 (0.61) and 1.424 (0.75) h.",Bioequivalence study of two mirtazapine oral tablet formulations in healthy Chinese male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22541842/),h,18.941,61947,DB06148,Mianserin
,22541842,t(1/2),"The main PK parameters of the mirtazapine test and reference tables were as follows: mean (SD) C(max), 58.715 (23.89) and 58.255 (22.34) ng/ml; AUC(0-t), 591.406 (186.79) and 596.339 (201.25) ng × h/ml; AUC(0-∞), 627.03 (201.39) and 631.521 (227.32) ng × h/ml; t(1/2), 18.941 (4.79) and 18.285 (3.91) h; t(max) 1.417 (0.61) and 1.424 (0.75) h.",Bioequivalence study of two mirtazapine oral tablet formulations in healthy Chinese male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22541842/),h,18.285,61948,DB06148,Mianserin
,22541842,t(max),"The main PK parameters of the mirtazapine test and reference tables were as follows: mean (SD) C(max), 58.715 (23.89) and 58.255 (22.34) ng/ml; AUC(0-t), 591.406 (186.79) and 596.339 (201.25) ng × h/ml; AUC(0-∞), 627.03 (201.39) and 631.521 (227.32) ng × h/ml; t(1/2), 18.941 (4.79) and 18.285 (3.91) h; t(max) 1.417 (0.61) and 1.424 (0.75) h.",Bioequivalence study of two mirtazapine oral tablet formulations in healthy Chinese male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22541842/),h,1.417,61949,DB06148,Mianserin
,22541842,t(max),"The main PK parameters of the mirtazapine test and reference tables were as follows: mean (SD) C(max), 58.715 (23.89) and 58.255 (22.34) ng/ml; AUC(0-t), 591.406 (186.79) and 596.339 (201.25) ng × h/ml; AUC(0-∞), 627.03 (201.39) and 631.521 (227.32) ng × h/ml; t(1/2), 18.941 (4.79) and 18.285 (3.91) h; t(max) 1.417 (0.61) and 1.424 (0.75) h.",Bioequivalence study of two mirtazapine oral tablet formulations in healthy Chinese male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22541842/),h,1.424,61950,DB06148,Mianserin
,15538128,total clearance of racemic mirtazapine (Cl/F),"Median total clearance of racemic mirtazapine (Cl/F) was 20.1, 39.7, and 49.8 L/h in carriers of 0, 2, and 3 active genes of CYP2D6 (P = 0.002, trend test) and the median maximum plasma concentrations were 129, 159, and 76 mug/L in these 3 groups.",Impact of the CYP2D6 ultrarapid metabolizer genotype on mirtazapine pharmacokinetics and adverse events in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15538128/),[l] / [h],20.1,77476,DB06148,Mianserin
,15538128,total clearance of racemic mirtazapine (Cl/F),"Median total clearance of racemic mirtazapine (Cl/F) was 20.1, 39.7, and 49.8 L/h in carriers of 0, 2, and 3 active genes of CYP2D6 (P = 0.002, trend test) and the median maximum plasma concentrations were 129, 159, and 76 mug/L in these 3 groups.",Impact of the CYP2D6 ultrarapid metabolizer genotype on mirtazapine pharmacokinetics and adverse events in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15538128/),[l] / [h],39.7,77477,DB06148,Mianserin
,15538128,total clearance of racemic mirtazapine (Cl/F),"Median total clearance of racemic mirtazapine (Cl/F) was 20.1, 39.7, and 49.8 L/h in carriers of 0, 2, and 3 active genes of CYP2D6 (P = 0.002, trend test) and the median maximum plasma concentrations were 129, 159, and 76 mug/L in these 3 groups.",Impact of the CYP2D6 ultrarapid metabolizer genotype on mirtazapine pharmacokinetics and adverse events in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15538128/),[l] / [h],49.8,77478,DB06148,Mianserin
,15538128,maximum plasma concentrations,"Median total clearance of racemic mirtazapine (Cl/F) was 20.1, 39.7, and 49.8 L/h in carriers of 0, 2, and 3 active genes of CYP2D6 (P = 0.002, trend test) and the median maximum plasma concentrations were 129, 159, and 76 mug/L in these 3 groups.",Impact of the CYP2D6 ultrarapid metabolizer genotype on mirtazapine pharmacokinetics and adverse events in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15538128/),[μg] / [l],129,77479,DB06148,Mianserin
,15538128,maximum plasma concentrations,"Median total clearance of racemic mirtazapine (Cl/F) was 20.1, 39.7, and 49.8 L/h in carriers of 0, 2, and 3 active genes of CYP2D6 (P = 0.002, trend test) and the median maximum plasma concentrations were 129, 159, and 76 mug/L in these 3 groups.",Impact of the CYP2D6 ultrarapid metabolizer genotype on mirtazapine pharmacokinetics and adverse events in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15538128/),[μg] / [l],159,77480,DB06148,Mianserin
,15538128,maximum plasma concentrations,"Median total clearance of racemic mirtazapine (Cl/F) was 20.1, 39.7, and 49.8 L/h in carriers of 0, 2, and 3 active genes of CYP2D6 (P = 0.002, trend test) and the median maximum plasma concentrations were 129, 159, and 76 mug/L in these 3 groups.",Impact of the CYP2D6 ultrarapid metabolizer genotype on mirtazapine pharmacokinetics and adverse events in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15538128/),[μg] / [l],76,77481,DB06148,Mianserin
,18514457,retention time,"The retention time of mianserin and cinnarizine was 3.4 and 2.1 min, respectively.",Determination of mianserin in human plasma by high performance liquid chromatography-electrospray ionization mass spectrometry (HPLC-ESI/MS): application to a bioequivalence study in Chinese volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18514457/),min,3.4,90863,DB06148,Mianserin
,18514457,retention time,"The retention time of mianserin and cinnarizine was 3.4 and 2.1 min, respectively.",Determination of mianserin in human plasma by high performance liquid chromatography-electrospray ionization mass spectrometry (HPLC-ESI/MS): application to a bioequivalence study in Chinese volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18514457/),min,2.1,90864,DB06148,Mianserin
,18514457,recovery,"The recovery was 81.3-84.1%, intra- and inter-day precision of the assay at three concentrations were 9.6-11.4% with accuracy of 97.5-101.2% and the lower limit of quantitation (LLOQ) detection was 1.0 ng/ml for mianserin.",Determination of mianserin in human plasma by high performance liquid chromatography-electrospray ionization mass spectrometry (HPLC-ESI/MS): application to a bioequivalence study in Chinese volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18514457/),%,81.3-84.1,90865,DB06148,Mianserin
,3830718,plasma clearance,"The mean plasma clearance of mianserin was found to be 19 +/- 2 l h-1 (mean +/- SEM), the kinetic volume of distribution 444 +/- 250 l, the steady-state volume of distribution 242 +/- 171 l and the elimination half-life 33 +/- 5 h.",Absolute bioavailability of mianserin tablets and solution in healthy humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3830718/),[l] / [h],19,96520,DB06148,Mianserin
,3830718,kinetic volume of distribution,"The mean plasma clearance of mianserin was found to be 19 +/- 2 l h-1 (mean +/- SEM), the kinetic volume of distribution 444 +/- 250 l, the steady-state volume of distribution 242 +/- 171 l and the elimination half-life 33 +/- 5 h.",Absolute bioavailability of mianserin tablets and solution in healthy humans. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3830718/),l,444,96521,DB06148,Mianserin
,3830718,steady-state volume of distribution,"The mean plasma clearance of mianserin was found to be 19 +/- 2 l h-1 (mean +/- SEM), the kinetic volume of distribution 444 +/- 250 l, the steady-state volume of distribution 242 +/- 171 l and the elimination half-life 33 +/- 5 h.",Absolute bioavailability of mianserin tablets and solution in healthy humans. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3830718/),l,242,96522,DB06148,Mianserin
,3830718,elimination half-life,"The mean plasma clearance of mianserin was found to be 19 +/- 2 l h-1 (mean +/- SEM), the kinetic volume of distribution 444 +/- 250 l, the steady-state volume of distribution 242 +/- 171 l and the elimination half-life 33 +/- 5 h.",Absolute bioavailability of mianserin tablets and solution in healthy humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3830718/),h,33,96523,DB06148,Mianserin
,3830718,absolute bioavailability,The absolute bioavailability in terms of extent of absorption was 22 +/- 3% for the solution and 20 +/- 3% for the tablets.,Absolute bioavailability of mianserin tablets and solution in healthy humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3830718/),%,22,96524,DB06148,Mianserin
,3830718,absolute bioavailability,The absolute bioavailability in terms of extent of absorption was 22 +/- 3% for the solution and 20 +/- 3% for the tablets.,Absolute bioavailability of mianserin tablets and solution in healthy humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3830718/),%,20,96525,DB06148,Mianserin
,3830718,peak level,The mean peak level for the solution was 79 +/- 11 ng X ml-1 and for the tablets 54 +/- 5 ng X ml-1; mean peak time for the solution was 1.1 +/- 0.2 h and for the tablets 1.4 +/- 0.2 h.,Absolute bioavailability of mianserin tablets and solution in healthy humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3830718/),[ng] / [ml],79,96526,DB06148,Mianserin
,3830718,peak level,The mean peak level for the solution was 79 +/- 11 ng X ml-1 and for the tablets 54 +/- 5 ng X ml-1; mean peak time for the solution was 1.1 +/- 0.2 h and for the tablets 1.4 +/- 0.2 h.,Absolute bioavailability of mianserin tablets and solution in healthy humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3830718/),[ng] / [ml],54,96527,DB06148,Mianserin
,3830718,peak time,The mean peak level for the solution was 79 +/- 11 ng X ml-1 and for the tablets 54 +/- 5 ng X ml-1; mean peak time for the solution was 1.1 +/- 0.2 h and for the tablets 1.4 +/- 0.2 h.,Absolute bioavailability of mianserin tablets and solution in healthy humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3830718/),h,1.1,96528,DB06148,Mianserin
,3830718,peak time,The mean peak level for the solution was 79 +/- 11 ng X ml-1 and for the tablets 54 +/- 5 ng X ml-1; mean peak time for the solution was 1.1 +/- 0.2 h and for the tablets 1.4 +/- 0.2 h.,Absolute bioavailability of mianserin tablets and solution in healthy humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3830718/),h,1.4,96529,DB06148,Mianserin
,3830718,absorption half-life,The mean absorption half-life for the solution was 0.43 +/- 0.13 h and for the tablets 0.39 +/- 0.11 h.(ABSTRACT TRUNCATED AT 250 WORDS),Absolute bioavailability of mianserin tablets and solution in healthy humans. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3830718/),h,0.43,96530,DB06148,Mianserin
,3830718,absorption half-life,The mean absorption half-life for the solution was 0.43 +/- 0.13 h and for the tablets 0.39 +/- 0.11 h.(ABSTRACT TRUNCATED AT 250 WORDS),Absolute bioavailability of mianserin tablets and solution in healthy humans. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3830718/),h,0.39,96531,DB06148,Mianserin
,17329996,rate constant,"Mirtazapine was enantioselectively absorbed from the gut with a rate constant of 0.2 min-1 for S+, but 0.08 min-1 for R- mirtazapine.",Pharmacokinetics of mirtazapine: enantioselective effects of the CYP2D6 ultra rapid metabolizer genotype and correlation with adverse effects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17329996/),1/[min],0.2,98098,DB06148,Mianserin
,17329996,rate constant,"Mirtazapine was enantioselectively absorbed from the gut with a rate constant of 0.2 min-1 for S+, but 0.08 min-1 for R- mirtazapine.",Pharmacokinetics of mirtazapine: enantioselective effects of the CYP2D6 ultra rapid metabolizer genotype and correlation with adverse effects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17329996/),1/[min],0.08,98099,DB06148,Mianserin
,17329996,total clearance,"Kinetics of R- mirtazapine was only marginally dependent on CYP2D6 genotype, but total clearance of the S+ enantiomer were 1.3, 2.3, and 3.4 L min-1 in poor, extensive, and ultrarapid metabolizers of CYP2D6 substrates with apparent substantial first-pass metabolism in rapid and ultrarapid metabolizers.",Pharmacokinetics of mirtazapine: enantioselective effects of the CYP2D6 ultra rapid metabolizer genotype and correlation with adverse effects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17329996/),[l] / [min],1.3,98100,DB06148,Mianserin
,17329996,total clearance,"Kinetics of R- mirtazapine was only marginally dependent on CYP2D6 genotype, but total clearance of the S+ enantiomer were 1.3, 2.3, and 3.4 L min-1 in poor, extensive, and ultrarapid metabolizers of CYP2D6 substrates with apparent substantial first-pass metabolism in rapid and ultrarapid metabolizers.",Pharmacokinetics of mirtazapine: enantioselective effects of the CYP2D6 ultra rapid metabolizer genotype and correlation with adverse effects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17329996/),[l] / [min],2.3,98101,DB06148,Mianserin
,17329996,total clearance,"Kinetics of R- mirtazapine was only marginally dependent on CYP2D6 genotype, but total clearance of the S+ enantiomer were 1.3, 2.3, and 3.4 L min-1 in poor, extensive, and ultrarapid metabolizers of CYP2D6 substrates with apparent substantial first-pass metabolism in rapid and ultrarapid metabolizers.",Pharmacokinetics of mirtazapine: enantioselective effects of the CYP2D6 ultra rapid metabolizer genotype and correlation with adverse effects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17329996/),[l] / [min],3.4,98102,DB06148,Mianserin
,22345050,run time,"Chromatography was performed isocratically on a C(18), 5 µm analytical column and the run time was 1.8 min.","A fast, sensitive and simple method for mirtazapine quantification in human plasma by HPLC-ESI-MS/MS. Application to a comparative bioavailability study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22345050/),min,1.8,115889,DB06148,Mianserin
,20969604,half-life,Median half-life was 15.9 h (HD) and 9.2 h (LD).,Studies on the pharmacokinetics and pharmacodynamics of mirtazapine in healthy young cats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20969604/),h,15.9,117645,DB06148,Mianserin
,20969604,half-life,Median half-life was 15.9 h (HD) and 9.2 h (LD).,Studies on the pharmacokinetics and pharmacodynamics of mirtazapine in healthy young cats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20969604/),h,9.2,117646,DB06148,Mianserin
,9034228,elimination half-lives,"The observed elimination half-lives of 19.7 +/- 3.0 h and 20.8 +/- 2.7 h (n = 20) for NOCTE and BID, respectively are in agreement with previous results.",Mirtazapine pharmacokinetics with two dosage regimens and two pharmaceutical formulations. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9034228/),h,19.7,131223,DB06148,Mianserin
,9034228,elimination half-lives,"The observed elimination half-lives of 19.7 +/- 3.0 h and 20.8 +/- 2.7 h (n = 20) for NOCTE and BID, respectively are in agreement with previous results.",Mirtazapine pharmacokinetics with two dosage regimens and two pharmaceutical formulations. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9034228/),h,20.8,131224,DB06148,Mianserin
,17665858,recovery,The recovery ranged from 86.1 to 94.5% for mianserin.,"Development, validation and application of the HPLC method for determination of mianserin in human serum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17665858/),%,86.1,131385,DB06148,Mianserin
,17665858,recovery,The recovery ranged from 86.1 to 94.5% for mianserin.,"Development, validation and application of the HPLC method for determination of mianserin in human serum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17665858/),%,94,131386,DB06148,Mianserin
,1711447,elimination half-life,Its elimination half-life of 33 hours permits once daily oral administration.,"Citalopram. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1711447/),h,33,167736,DB06148,Mianserin
,7075657,peak blood concentration,The peak blood concentration observed was 65 microgram/1 at 3 h following the dose.,A pharmacokinetic study of mianserin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7075657/),μg,65,191473,DB06148,Mianserin
,7075657,(,"Mean kinetic parameters (and range) calculated from the blood concentrations were: (t1/2)abs 1.1 h (0.3-2.8), (t1/2) alpha 2.5 h (0.9-4.7), (t1/2) beta 21 h (14-33), (Vd) beta 27.5 l/kg (16.8-46.5) and Cloral 0.98 l/kg/h (0.47-1.75).",A pharmacokinetic study of mianserin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7075657/),h,1.1,191474,DB06148,Mianserin
,7075657,t1/2)abs,"Mean kinetic parameters (and range) calculated from the blood concentrations were: (t1/2)abs 1.1 h (0.3-2.8), (t1/2) alpha 2.5 h (0.9-4.7), (t1/2) beta 21 h (14-33), (Vd) beta 27.5 l/kg (16.8-46.5) and Cloral 0.98 l/kg/h (0.47-1.75).",A pharmacokinetic study of mianserin. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7075657/),h,1.1,191475,DB06148,Mianserin
,7075657,t1/2) alpha,"Mean kinetic parameters (and range) calculated from the blood concentrations were: (t1/2)abs 1.1 h (0.3-2.8), (t1/2) alpha 2.5 h (0.9-4.7), (t1/2) beta 21 h (14-33), (Vd) beta 27.5 l/kg (16.8-46.5) and Cloral 0.98 l/kg/h (0.47-1.75).",A pharmacokinetic study of mianserin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7075657/),h,2.5,191476,DB06148,Mianserin
,7075657,t1/2) beta,"Mean kinetic parameters (and range) calculated from the blood concentrations were: (t1/2)abs 1.1 h (0.3-2.8), (t1/2) alpha 2.5 h (0.9-4.7), (t1/2) beta 21 h (14-33), (Vd) beta 27.5 l/kg (16.8-46.5) and Cloral 0.98 l/kg/h (0.47-1.75).",A pharmacokinetic study of mianserin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7075657/),h,21,191477,DB06148,Mianserin
,7075657,Vd) beta,"Mean kinetic parameters (and range) calculated from the blood concentrations were: (t1/2)abs 1.1 h (0.3-2.8), (t1/2) alpha 2.5 h (0.9-4.7), (t1/2) beta 21 h (14-33), (Vd) beta 27.5 l/kg (16.8-46.5) and Cloral 0.98 l/kg/h (0.47-1.75).",A pharmacokinetic study of mianserin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7075657/),[l] / [kg],27.5,191478,DB06148,Mianserin
,7075657,Cloral,"Mean kinetic parameters (and range) calculated from the blood concentrations were: (t1/2)abs 1.1 h (0.3-2.8), (t1/2) alpha 2.5 h (0.9-4.7), (t1/2) beta 21 h (14-33), (Vd) beta 27.5 l/kg (16.8-46.5) and Cloral 0.98 l/kg/h (0.47-1.75).",A pharmacokinetic study of mianserin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7075657/),[l] / [h·kg],0.98,191479,DB06148,Mianserin
,7075657,Blood/plasma concentration ratios,Blood/plasma concentration ratios ranged from 0.50-0.74.,A pharmacokinetic study of mianserin. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7075657/),,0.50-0.74,191480,DB06148,Mianserin
,15315787,flow rate,"The chromatographic separation of the (+)-(S)- and (-)-(R)-enantiomers of mirtazapine was achieved on a Chiralpak AD column (250 mm x 4.6 mm, 10 microm particle size) protected with a CN guard column, using hexane-ethanol (98:2, v/v) plus 0.1% diethylamine as the isocratic mobile phase, at a flow rate of 1.2 ml/min.",New method for the chiral evaluation of mirtazapine in human plasma by liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15315787/),[ml] / [min],1.2,192825,DB06148,Mianserin
less,15315787,total analysis time,The total analysis time was less than 12 min per sample.,New method for the chiral evaluation of mirtazapine in human plasma by liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15315787/),-1·min,12,192826,DB06148,Mianserin
,15315787,recoveries,The recoveries of (+)-(S)- and (-)-(R)-mirtazapine were in the 88-111% range with a linear response over the 6.25-625 ng/ml concentration range for both enantiomers.,New method for the chiral evaluation of mirtazapine in human plasma by liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15315787/),%,88-111,192827,DB06148,Mianserin
,15315787,quantification limit (LOQ),The quantification limit (LOQ) was 5 ng/ml.,New method for the chiral evaluation of mirtazapine in human plasma by liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15315787/),[ng] / [ml],5,192828,DB06148,Mianserin
,10885584,absolute bioavailability,"The absolute bioavailability is approximately 50%, mainly because of gut wall and hepatic first-pass metabolism.",Clinical pharmacokinetics of mirtazapine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10885584/),%,50,193151,DB06148,Mianserin
,10885584,elimination half-life,"The elimination half-life of mirtazapine ranges from 20 to 40 hours, which is in agreement with the time to reach steady state (4 to 6 days).",Clinical pharmacokinetics of mirtazapine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10885584/),h,20 to 40,193152,DB06148,Mianserin
,10885584,time to reach steady state,"The elimination half-life of mirtazapine ranges from 20 to 40 hours, which is in agreement with the time to reach steady state (4 to 6 days).",Clinical pharmacokinetics of mirtazapine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10885584/),d,4 to 6,193153,DB06148,Mianserin
,10885584,Total body clearance,Total body clearance as determined from intravenous administration to young males amounts to 31 L/h.,Clinical pharmacokinetics of mirtazapine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10885584/),[l] / [h],31,193154,DB06148,Mianserin
,10885584,half-life,"The pharmacokinetics of mirtazapine appears to be enantioselective, resulting in higher plasma concentrations and longer half-life of the (R)-(-)-enantiomer (18.0 +/-2.5h) compared with that of the (S)-(+)-enantiomer (9.9+/-3. lh).",Clinical pharmacokinetics of mirtazapine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10885584/),h,18.0,193155,DB06148,Mianserin
,10885584,half-life,"The pharmacokinetics of mirtazapine appears to be enantioselective, resulting in higher plasma concentrations and longer half-life of the (R)-(-)-enantiomer (18.0 +/-2.5h) compared with that of the (S)-(+)-enantiomer (9.9+/-3. lh).",Clinical pharmacokinetics of mirtazapine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10885584/),h,9.9,193156,DB06148,Mianserin
,19429471,dose/weight adjusted AUC(0-infinity),"Attending to the theoretical figures provided by the model, mean (95% CI) dose/weight adjusted AUC(0-infinity) (ng h/ml)/(mg/kg) is 1516.62 (1411.27-1628.22) in EM/UM, 1613.63 (1482.14-1758.55) in IM and 2049.28 (1779.78-2357.24) in PM.","Influence of sex and CYP2D6 genotype on mirtazapine disposition, evaluated in Spanish healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19429471/),[h·ml·ng] / [kg·mg],1516.62,195558,DB06148,Mianserin
,19429471,dose/weight adjusted AUC(0-infinity),"Attending to the theoretical figures provided by the model, mean (95% CI) dose/weight adjusted AUC(0-infinity) (ng h/ml)/(mg/kg) is 1516.62 (1411.27-1628.22) in EM/UM, 1613.63 (1482.14-1758.55) in IM and 2049.28 (1779.78-2357.24) in PM.","Influence of sex and CYP2D6 genotype on mirtazapine disposition, evaluated in Spanish healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19429471/),[h·ml·ng] / [kg·mg],1613.63,195559,DB06148,Mianserin
,19429471,dose/weight adjusted AUC(0-infinity),"Attending to the theoretical figures provided by the model, mean (95% CI) dose/weight adjusted AUC(0-infinity) (ng h/ml)/(mg/kg) is 1516.62 (1411.27-1628.22) in EM/UM, 1613.63 (1482.14-1758.55) in IM and 2049.28 (1779.78-2357.24) in PM.","Influence of sex and CYP2D6 genotype on mirtazapine disposition, evaluated in Spanish healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19429471/),[h·ml·ng] / [kg·mg],2049.28,195560,DB06148,Mianserin
,19429471,AUC(0-infinity),Females show a lower dose/weight adjusted AUC(0-infinity): 1594.39 (1477.70-1720.28) vs. 1837.65 (1694.67-1992.70).,"Influence of sex and CYP2D6 genotype on mirtazapine disposition, evaluated in Spanish healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19429471/),,1594.39,195561,DB06148,Mianserin
,19429471,AUC(0-infinity),Females show a lower dose/weight adjusted AUC(0-infinity): 1594.39 (1477.70-1720.28) vs. 1837.65 (1694.67-1992.70).,"Influence of sex and CYP2D6 genotype on mirtazapine disposition, evaluated in Spanish healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19429471/),,1837.65,195562,DB06148,Mianserin
,19429471,dose,On the contrary dose/weight adjusted C(max) is higher in females than in males: 38.33 (34.79-42.28) vs. 32.66 (29.44-36.21).,"Influence of sex and CYP2D6 genotype on mirtazapine disposition, evaluated in Spanish healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19429471/),,38.33,195563,DB06148,Mianserin
,19429471,C(max),On the contrary dose/weight adjusted C(max) is higher in females than in males: 38.33 (34.79-42.28) vs. 32.66 (29.44-36.21).,"Influence of sex and CYP2D6 genotype on mirtazapine disposition, evaluated in Spanish healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19429471/),,38.33,195564,DB06148,Mianserin
,19429471,C(max),On the contrary dose/weight adjusted C(max) is higher in females than in males: 38.33 (34.79-42.28) vs. 32.66 (29.44-36.21).,"Influence of sex and CYP2D6 genotype on mirtazapine disposition, evaluated in Spanish healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19429471/),,32.66,195565,DB06148,Mianserin
,21985134,half-life,Mean half-life ± SD was 15.2 ± 4.2 hours (CKD) and 12.1 ± 1.1 hours (AMC).,The pharmacokinetics of mirtazapine in cats with chronic kidney disease and in age-matched control cats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21985134/),h,15.2,203462,DB06148,Mianserin
,21985134,half-life,Mean half-life ± SD was 15.2 ± 4.2 hours (CKD) and 12.1 ± 1.1 hours (AMC).,The pharmacokinetics of mirtazapine in cats with chronic kidney disease and in age-matched control cats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21985134/),h,12.1,203463,DB06148,Mianserin
,21985134,area under the curve (AUC),Mean area under the curve (AUC) ± SD was 770.6 ± 225.5 ng/mL•hr (CKD) and 555.5 ± 175.4 ng/mL•hr (AMC).,The pharmacokinetics of mirtazapine in cats with chronic kidney disease and in age-matched control cats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21985134/),[ng] / [h·ml],770.6,203464,DB06148,Mianserin
,21985134,area under the curve (AUC),Mean area under the curve (AUC) ± SD was 770.6 ± 225.5 ng/mL•hr (CKD) and 555.5 ± 175.4 ng/mL•hr (AMC).,The pharmacokinetics of mirtazapine in cats with chronic kidney disease and in age-matched control cats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21985134/),[ng] / [h·ml],555.5,203465,DB06148,Mianserin
,21985134,CL/F,Mean CL/F ± SD was 0.6 ± 0.1 L/hr/kg (CKD) and 0.8 ± 0.16 L/hr/kg (AMC).,The pharmacokinetics of mirtazapine in cats with chronic kidney disease and in age-matched control cats. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21985134/),[l] / [h·kg],0.6,203466,DB06148,Mianserin
,21985134,CL/F,Mean CL/F ± SD was 0.6 ± 0.1 L/hr/kg (CKD) and 0.8 ± 0.16 L/hr/kg (AMC).,The pharmacokinetics of mirtazapine in cats with chronic kidney disease and in age-matched control cats. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21985134/),[l] / [h·kg],0.8,203467,DB06148,Mianserin
,21985134,accumulation factor,Calculated accumulation factor for 48-hour dosing in CKD cats was 1.15.,The pharmacokinetics of mirtazapine in cats with chronic kidney disease and in age-matched control cats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21985134/),,1.15,203468,DB06148,Mianserin
,25078020,concentration,Median mirtazapine concentration was 43.6 μg/L (164.37 nmol) at a daily dosage range of 7.5-60 mg.,Therapeutic drug monitoring of mirtazapine in a routine outpatient setting in Asian psychiatric patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25078020/),[μg] / [l],43.6,215752,DB06148,Mianserin
,25078020,concentration-to-dose (C/D) ratio,"Mean concentration-to-dose (C/D) ratio was 1.48 μg/L/mg/day (5.58 nmol/mg/day), which was higher than that in a previous study in Caucasian subjects.",Therapeutic drug monitoring of mirtazapine in a routine outpatient setting in Asian psychiatric patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25078020/),[μg] / [d·l·mg],1.48,215753,DB06148,Mianserin
,25078020,concentration-to-dose (C/D) ratio,"Mean concentration-to-dose (C/D) ratio was 1.48 μg/L/mg/day (5.58 nmol/mg/day), which was higher than that in a previous study in Caucasian subjects.",Therapeutic drug monitoring of mirtazapine in a routine outpatient setting in Asian psychiatric patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25078020/),[nM] / [d·mg],5.58,215754,DB06148,Mianserin
,14726991,initial clearance from blood to tissue (K1),"[N-methyl-11C]Mirtazapine entered the brain readily, with initial clearance from blood to tissue (K1) ranging from 0.31 ml/ml/min in amygdala to 0.54 ml/ml/min in thalamus.",[N-methyl-11C]Mirtazapine for positron emission tomography neuroimaging of antidepressant actions in humans. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14726991/),[ml] / [min·ml],0.31,230710,DB06148,Mianserin
,14726991,initial clearance from blood to tissue (K1),"[N-methyl-11C]Mirtazapine entered the brain readily, with initial clearance from blood to tissue (K1) ranging from 0.31 ml/ml/min in amygdala to 0.54 ml/ml/min in thalamus.",[N-methyl-11C]Mirtazapine for positron emission tomography neuroimaging of antidepressant actions in humans. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14726991/),[ml] / [min·ml],0.54,230711,DB06148,Mianserin
,14726991,clearance,The clearance of [N-methyl-11C]mirtazapine from the tissue compartment (k2') ranged from a low of 0.03 min(-1) in amygdala to a high of 0.06-0.07 min(-1) in thalamus and cerebellum.,[N-methyl-11C]Mirtazapine for positron emission tomography neuroimaging of antidepressant actions in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14726991/),1/[min],0.03,230712,DB06148,Mianserin
,14726991,clearance,The clearance of [N-methyl-11C]mirtazapine from the tissue compartment (k2') ranged from a low of 0.03 min(-1) in amygdala to a high of 0.06-0.07 min(-1) in thalamus and cerebellum.,[N-methyl-11C]Mirtazapine for positron emission tomography neuroimaging of antidepressant actions in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14726991/),1/[min],0.06-0.07,230713,DB06148,Mianserin
,14726991,volume of distribution (Ve'),"The volume of distribution (Ve') of [N-methyl-11C]mirtazapine was markedly greater in hippocampus and amygdala (11.3-12.0) than in cerebellum (6.7), with intermediate levels in the thalamus (9.4).",[N-methyl-11C]Mirtazapine for positron emission tomography neuroimaging of antidepressant actions in humans. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14726991/),,11,230714,DB06148,Mianserin
,14726991,volume of distribution (Ve'),"The volume of distribution (Ve') of [N-methyl-11C]mirtazapine was markedly greater in hippocampus and amygdala (11.3-12.0) than in cerebellum (6.7), with intermediate levels in the thalamus (9.4).",[N-methyl-11C]Mirtazapine for positron emission tomography neuroimaging of antidepressant actions in humans. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14726991/),,6.7,230715,DB06148,Mianserin
,14726991,volume of distribution (Ve'),"The volume of distribution (Ve') of [N-methyl-11C]mirtazapine was markedly greater in hippocampus and amygdala (11.3-12.0) than in cerebellum (6.7), with intermediate levels in the thalamus (9.4).",[N-methyl-11C]Mirtazapine for positron emission tomography neuroimaging of antidepressant actions in humans. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14726991/),,9.4,230716,DB06148,Mianserin
,22877221,turnaround time,"The approach allows for the investigation of a set of six compounds simultaneously, with a turnaround time of 1 week or less.",A semi-automated method for the integrated evaluation of half-life and metabolic soft spots of discovery compounds. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22877221/),week,1,231407,DB06148,Mianserin
,14515060,area under the curve (AUC),A unimodal distribution of bupropion and hydroxybupropion kinetic parameters was detected with a mean (range) area under the curve (AUC) of 3.64 (0.89-8.14) micromol.h/l for bupropion and 25.5 (6.72-75.3) micromol.h/l for hydroxybupropion.,Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14515060/),[h·μM] / [l],3.64,234498,DB06148,Mianserin
,14515060,area under the curve (AUC),A unimodal distribution of bupropion and hydroxybupropion kinetic parameters was detected with a mean (range) area under the curve (AUC) of 3.64 (0.89-8.14) micromol.h/l for bupropion and 25.5 (6.72-75.3) micromol.h/l for hydroxybupropion.,Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14515060/),[h·μM] / [l],25.5,234499,DB06148,Mianserin
,11929701,K1,"[N-methyl-11C]Mianserin entered most brain regions readily (range of K1 values: 0.66-1.13), reaching highest levels in the basal ganglia and thalamus.","PET evaluation of a tetracyclic, atypical antidepressant, [N-methyl-11C]mianserin, in the living porcine brain. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11929701/),,0.66-1.13,244674,DB06148,Mianserin
,21652240,half-life,The mean half-life of MRT was 6.17 h with a clearance of 1193 mL/h/kg.,Pharmacokinetics of mirtazapine and its main metabolites in Beagle dogs: a pilot study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21652240/),h,6.17,249192,DB06148,Mianserin
,21652240,clearance,The mean half-life of MRT was 6.17 h with a clearance of 1193 mL/h/kg.,Pharmacokinetics of mirtazapine and its main metabolites in Beagle dogs: a pilot study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21652240/),[ml] / [h·kg],1193,249193,DB06148,Mianserin
,413141,beta-phase half-life,"Plasma levels peak at 2 h with a median level of 11.0 ng/ml, a median beta-phase half-life of 10.0 h, and a median apparent volume of distribution of 3.3 X 10(3) 1.","EEG, blood level, and behavioral effects of the antidepressant mianserin (ORG GB-94). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/413141/),h,10.0,252337,DB06148,Mianserin
,413141,apparent volume of distribution,"Plasma levels peak at 2 h with a median level of 11.0 ng/ml, a median beta-phase half-life of 10.0 h, and a median apparent volume of distribution of 3.3 X 10(3) 1.","EEG, blood level, and behavioral effects of the antidepressant mianserin (ORG GB-94). ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/413141/),1,3.3 X 10(3),252338,DB06148,Mianserin
greater,2719901,half-lives,All had half-lives greater than or equal to 2.5 days with a mean of 6 +/- 2.8 (s.d.) days.,Variability in the elimination of mianserin in elderly patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2719901/),d,2.5,265376,DB06148,Mianserin
,2719901,half-lives,All had half-lives greater than or equal to 2.5 days with a mean of 6 +/- 2.8 (s.d.) days.,Variability in the elimination of mianserin in elderly patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2719901/),d,6,265377,DB06148,Mianserin
,27190632,maximum plasma mianserin concentration (Cmax),"In dogs, the maximum plasma mianserin concentration (Cmax) was 1.3 ± 0.4 ng/mL, the time to Cmax (tmax) was 5.5 ± 4.3 h, and the area under the plasma concentration-time curve from 0 to 24 h (AUC0-24) was 18.9 ± 1.9 h・ng/mL.",The pharmacokinetics of mianserin suppositories for rectal administration in dogs and healthy volunteers: a pilot study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27190632/),[ng] / [ml],1.3,267247,DB06148,Mianserin
,27190632,time to Cmax (tmax),"In dogs, the maximum plasma mianserin concentration (Cmax) was 1.3 ± 0.4 ng/mL, the time to Cmax (tmax) was 5.5 ± 4.3 h, and the area under the plasma concentration-time curve from 0 to 24 h (AUC0-24) was 18.9 ± 1.9 h・ng/mL.",The pharmacokinetics of mianserin suppositories for rectal administration in dogs and healthy volunteers: a pilot study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27190632/),h,5.5,267248,DB06148,Mianserin
,27190632,area under the plasma concentration-time curve from 0 to 24 h (AUC0-24),"In dogs, the maximum plasma mianserin concentration (Cmax) was 1.3 ± 0.4 ng/mL, the time to Cmax (tmax) was 5.5 ± 4.3 h, and the area under the plasma concentration-time curve from 0 to 24 h (AUC0-24) was 18.9 ± 1.9 h・ng/mL.",The pharmacokinetics of mianserin suppositories for rectal administration in dogs and healthy volunteers: a pilot study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27190632/),[h・ng] / [ml],18.9,267249,DB06148,Mianserin
,27190632,Cmax,"In humans, the Cmax was 14.6 ± 6.3 ng/mL, the tmax was 8 h, and the AUC0-24 was 266 ± 103 h・ng/mL.",The pharmacokinetics of mianserin suppositories for rectal administration in dogs and healthy volunteers: a pilot study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27190632/),[ng] / [ml],14.6,267250,DB06148,Mianserin
,27190632,tmax,"In humans, the Cmax was 14.6 ± 6.3 ng/mL, the tmax was 8 h, and the AUC0-24 was 266 ± 103 h・ng/mL.",The pharmacokinetics of mianserin suppositories for rectal administration in dogs and healthy volunteers: a pilot study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27190632/),h,8,267251,DB06148,Mianserin
,27190632,AUC0-24,"In humans, the Cmax was 14.6 ± 6.3 ng/mL, the tmax was 8 h, and the AUC0-24 was 266 ± 103 h・ng/mL.",The pharmacokinetics of mianserin suppositories for rectal administration in dogs and healthy volunteers: a pilot study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27190632/),[h・ng] / [ml],266,267252,DB06148,Mianserin
